-
Tumor Microenvironment (TME)
-
Tumor Microenvironment (TME)
Cytotoxic T-cells (CTLs) in the tumor microenvironment (TME) orchestrate anti-tumor immunity. Immuno
...
-
Tumor Microenvironment (TME)
-
Tumor Microenvironment (TME)
-
Clinical Development
FDA on going design requirements Applications to C> Global impact Cohort management
-
Translational Research
From checkpoint inhibitors towards neoepitope vaccines, does one size fits it all? Fit for purpose i
...
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
Afternoon Refreshments
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
Evening Drinks Reception
-
Tumor Microenvironment (TME)
-
Tumor Microenvironment (TME)
Induction of checkpoints and other components of tumor immunity Breaching the TME Tumor cell killing
...
-
Clinical Development
How to accelerate the determination of safety and clinical benefit Can the assessment of immune chan
...
-
Immune Biomarkers
Complex immune system Identifying biomarkers predictive of response to immunotherapy Technical chall
...
-
Translational Research
Multiple myeloma (MM) is a cancer of plasma cells with approximately 200,000 new cases/year and a 54
...
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
The Tumor Immune Microenvironment (TIME) plays a crucial role in response to immunotherapies, the en
...
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
1-2-1 Meetings / Networking Break
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
1-2-1 Meetings / Networking Break
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
The applications of next-generation sequencing (NGS) are playing an emerging role in immune-oncology
...
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
Networking Lunch
-
Immune Biomarkers
How can multiomics approaches on tissue samples drive deeper insights into immune system interaction
...
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
Morning Refreshments
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
1-2-1 Meetings / Networking Break
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
1-2-1 Meetings / Networking Break
-
Tumor Microenvironment (TME)
-
Tumor Microenvironment (TME)
-
Clinical Development
Why is resistance (e.g., primary and secondary) to PD(L1)-1 inhibitors a significant clinical proble
...
-
Translational Research
Ways to determine FiH dose for oncology trials with immune cell engaging multi-specific antibodies A
...
-
Immune Biomarkers
Is it ready for prime time? Do we have sufficient data? Is there consensus around a standardized as
...
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
Dynamic interactions within the tumor microenvironment influence patient responses to immune-modulat
...
-
-
Clinical Development
-
Immune Biomarkers
-
Translational Research
-
Tumor Microenvironment (TME)
Registration
)
Cytotoxic T-cells (CTLs) in the tumor microenvironment (TME) orchestrate anti-tumor immunity. Immuno ...)
FDA on going design requirements Applications to C> Global impact Cohort management)
From checkpoint inhibitors towards neoepitope vaccines, does one size fits it all? Fit for purpose i ...)
Multiple myeloma (MM) is a cancer of plasma cells with approximately 200,000 new cases/year and a 54 ...)
The Tumor Immune Microenvironment (TIME) plays a crucial role in response to immunotherapies, the en ...)
The applications of next-generation sequencing (NGS) are playing an emerging role in immune-oncology ...)
How can multiomics approaches on tissue samples drive deeper insights into immune system interaction ...
)
)
)
)
)
)
)
)
)
)
)
)
)